Aerami Therapeutics

📍 Durham, United States🗓 Founded 2010👥 13 employees💰 Last funded Sep 2018
Biotechnology Research🌐 aerami.com
Website LinkedIn
Aerami Therapeutics is breathing life into the treatment of serious and rare cardiopulmonary conditions with a mission-driven objective: develop products that help patients live longer and help them live better. We do this by combining precision medicines and advanced administration platforms that support ease-of-use and quality-of-life. Our lead program, AER-901 (inhaled imatinib) in pulmonary hypertension, has been intentionally designed to potentially reverse the damage caused by disease progression while overcoming many of the limitations of oral, parenteral, and other inhaled delivery technologies. To learn more, visit: https://aerami.com/ #Aerami #Cardiopulmonary #PulmonaryHypertension #PulmonaryArterialHypertension #PH #PAH #ILD #HeartDisease #LungDisease #InhaledTherapeutics #AER901 #AER601
3
Total investors
0
Early stage
1
Mid stage
2
Late stage
2010
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2014–2018 · investors recorded per year
201412017120181
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Aerami Therapeutics?
Aerami Therapeutics has 3 investors on record on gritt.io, 1 mid-stage and 2 late-stage investors.
When did Aerami Therapeutics last raise funding?
The most recent investment in Aerami Therapeutics recorded on gritt.io was in September 2018.
When was Aerami Therapeutics founded?
Aerami Therapeutics was founded in 2010.
What industry is Aerami Therapeutics in?
Aerami Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Aerami Therapeutics based?
Aerami Therapeutics is headquartered in Durham, United States.